generalized myasthenia gravis gmg epidemiology forecast

Generalized Myasthenia Gravis (gMG) Insights and Trends

• Based on DelveInsight's assessment in 2025, the 7MM had approximately 200,000 diagnosed prevalent cases of gMG, with projections indicating a growing trend and an estimated CAGR during the forecast period (2026-2036).
• According to DelveInsight’s analysis, diagnosed prevalent cases of gMG were stratified into four age groups: 0–17 years, 18–49 years, 50–64 years, and 65 years and above. In the US in 2025, the largest share of cases, accounting for about 52% of the total, occurred in patients aged 65 years and above, followed by those aged 50–64 years, 18–49 years, and 0–17 years.
• In 2025, the United States accounted for ~90,000 diagnosed prevalent cases of gMG, underscoring a substantial patient base driving sustained demand.
• In 2025, based on DelveInsight’s assessment, the EU4 and the UK accounted for approximately 80,000 diagnosed prevalent cases of gMG, with projections indicating a rising trend and an expected compound annual growth rate over the forecast period from 2026 to 2036.
• As per DelveInsight’s assessment, from 2022 to 2036, the severity-specific diagnosed prevalent cases of Myasthenia Gravis in the US are expected to increase across MGFA classes, with Class II (mild generalized) accounting for the highest proportion of cases.
• In 2025, approximately 47% of gMG cases in Japan were male, while 53% were female. These numbers are expected to increase by 2036. The gender difference in myasthenia gravis may stem from immunological and hormonal variations, with females generally exhibiting higher autoimmune susceptibility compared to males.
• Advances in diagnostic pathways, including increased use of autoantibody testing (e.g., anti-AChR and anti-MuSK antibodies), electrophysiological studies, and improved clinical recognition, are enabling earlier identification of gMG and facilitating timely diagnosis.

Generalized Myasthenia Gravis (gMG) Epidemiology Forecast

• 2025 gMG Diagnosed Prevalent Cases in 7MM: ~200,000
• gMG Growth Rate (2026–2036) in the 7MM: ~2.25% CAGR

DelveInsight's ‘Generalized Myasthenia Gravis (gMG) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of gMG, historical and forecasted epidemiology trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Generalized Myasthenia Gravis (gMG) epidemiology report provides a comprehensive analysis of prevalent cases, capturing the number of diagnosed patients across the 7MM. It includes detailed segmentation by serology, age, severity, and gender, along with regional distribution. The report evaluates historical and forecasted prevalence trends (2026–2036), highlighting variations in disease occurrence and diagnosis patterns, and offering insights into the evolving burden of newly diagnosed gMG cases.

Geography Covered

• North America: The United States
• Europe: Germany, France, Italy, Spain and the UK
• Asia-Pacific: Japan

Generalized Myasthenia Gravis (gMG) Understanding

Generalized Myasthenia Gravis (gMG) Overview and Diagnosis

Generalized Myasthenia Gravis (gMG), is an autoimmune disease in which the immune system attacks the body’s tissues. In myasthenia gravis, the attack interrupts the connection between nerve and muscle the neuromuscular junction. Myasthenia gravis is characterized by autoantibodies against the Acetylcholine Receptor Antibody (AChR-Ab) or against a receptor-associated protein called Muscle-specific tyrosine Kinase Antibody (MuSK-Ab).

The clinical diagnosis of gMG is confirmed by Electromyography (EMG) studies, pharmacologic testing, and serum Ab assay. Positive results on EMG confirm a postsynaptic defect of the NMT, the clinical response to Cholinesterase Inhibitors (ChE-Is) supports myasthenia gravis diagnosis, and detection of specific Abs confirms gMG and identifies ab-related subgroups. EMG confirmation is crucial in patients with neither AChR nor MuSK Abs on the standard assay.

Further details are provided in the report.

Generalized Myasthenia Gravis (gMG) Epidemiology

Key Findings from Generalized Myasthenia Gravis (gMG) Epidemiological Analysis and Forecast

• In 2025, Myasthenia Gravis accounted for ~135,000 diagnosed prevalent cases in the US.
• Among the gender-specific cases of gMG, the majority was occupied by female accounting for ~60% of the cases in the US in 2025.
• In 2025, the highest disease burden of gMG was observed in patients aged =65 years, accounting for ~100,000 cases across the 7MM, highlighting a predominantly elderly patient population.
• In 2025, by antibody serology, Anti-AChR antibody–positive cases accounted for ~80% of patients with gMG in the EU4 and the UK, representing the dominant disease subtype.
• In 2025, Japan recorded the highest number of diagnosed prevalent myasthenia gravis cases under the MGFA classification in Class II with 16,000 cases, followed by Class I with 12,000 cases. By 2036, the number of diagnosed myasthenia gravis cases in Japan is projected to rise significantly within the MGFA classification.

Industry Experts and Physician Views for Generalized Myasthenia Gravis (gMG)

To keep up with gMG epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the gMG epidemiology, prevalence trends, regional distribution, patient demographics, diagnostic rates, and real-world disease burden patterns in gMG, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts engaged with 10+ key opinion leaders (KOLs) across major markets to capture country-level insights in generalized Myasthenia Gravis. Leading centers such as University of California and Royal College of Physicians, among others, were consulted to validate clinical practices, treatment patterns, and emerging therapeutic perspectives.

Their opinion helps understand and validate gMG epidemiological trends, highlight key gaps in diagnosis and disease burden, provide deeper epidemiological context, and support strategic decisions for patient identification and disease monitoring in gMG.

Scope of the Report

The report covers a segment of key epidemiological highlights, an executive summary, and a descriptive overview of gMG, including its causes, risk factors, and factors influencing disease occurrence.

Comprehensive insights are provided into prevalence trends and forecasts, along with the future growth potential of diagnosis rates and evolving patterns of disease detection across the 7MM.

Additionally, the report includes detailed segmentation of prevalent cases by histological subtype, age, gender, and region, offering a granular view of the epidemiological landscape.

A thorough assessment of historical and forecasted prevalence data, along with underlying assumptions and methodology, is included, providing a clear understanding of disease burden across the 7MM.

The report provides strategic insights by highlighting trends in prevalence, diagnostic gaps, and regional variations, supported by expert opinions and epidemiological analysis to better understand and project the gMG disease burden.

Report Insights

• gMG prevalence forecast, epidemiological burden, segmentation, trends, and opportunity assessment.

Report Key Strengths

• Epidemiology-based (EPI - based) bottom-up forecasting
• Artificial Intelligence (AI) - enabled epidemiology research report
• 11-year forecast
• gMG epidemiological outlook (North America, Europe, Asia-Pacific)
• gMG Burden trends (by geography)
• Report Assessment
• gMG Diagnostic Trends
• gMG Epidemiological Gaps
• gMG Development Trends
• gMG Emerging Research Focus
• gMG Disease Burden Attractiveness
• gMG Qualitative Epidemiological Insights

FAQs

• What was the gMG prevalent patient population and distribution (%) in 2025, and how will it evolve by 2036? What factors are driving these trends?
• What are the anticipated variations in prevalence and diagnosis rates across different geographies?
• What will be the future diagnosis and epidemiological trends of gMG?
• What are the disease risks, burden, and key epidemiological gaps in gMG? What are the growth opportunities based on the patient population across the 7MM?
• How will changes in prevalence and diagnosis impact the overall epidemiological landscape?
• What are the current diagnosis practices and epidemiology trends of gMG in the US, Europe, UK, and Japan?

Reasons to Buy

• The report will help in developing strategies by understanding the latest trends and changing epidemiology of gMG.
• Bottom-up forecasting builds from the prevalent patient population, delivering a robust, data-driven epidemiological approach.
• Insights on patient burden/prevalence, evolution in diagnosis, and factors contributing to changes in disease epidemiology during the forecast years.
• Understand the epidemiological opportunities across varying geographies and growth potential over the coming years.
• Identifying key trends in disease prevalence will help anticipate shifts in the epidemiological landscape.
• Detailed analysis and segmentation of prevalent cases to provide visibility around high-burden patient groups.
• To understand KOLs’ perspectives on diagnosis challenges and gaps in disease identification.
• Detailed insights on epidemiological unmet needs to support improved disease tracking and diagnosis strategies.
• This Artificial Intelligence (AI)-enabled report summarizes complex epidemiological datasets into clear, actionable insights for stakeholders, investors, and healthcare providers.